Loading patent…
OwnerHanmei Xuinventor
Estimating the term…
a highly efficient antiangiogenesis agent, which is a polypeptide for inhibition of angiogenesis Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, connected with a polypeptide containing Arg-Gly-Asp on its one end or two ends is provided. The inhibiting agent can be synthesized or gene engineered. It also relates to a physiochemical method for modifying the antiangiogenesis agent. Polypeptides with weight percentage of 1-70% preferably about 20-50% are mixed with 20%-95% polyethylene glycol, or heparin, or dextran, or polyvinylpyrrolidone, or polyethylene glycol-poly-amino acid copolymer, or palmitic acid or poly-sialic acid or liposomes solutions; preferably about 50-93% of the above modified substances are fully mixed even and shaken at a shaker at 4° C.-40° C., preferably 25° C.-37° C. for more than 10 min, and the modified substances are separated through appropriate methods. Furthermore, it still relates to the use of the above polypeptides and the polypeptide modified substances for manufacturing medicaments for treating human solid tumors.
A highly efficient antiangiogenesis agent, wherein at the both ends of the polypeptide Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro of antiangiogenesis agent, at least one end is bound with polypeptides with binding effect and affinity with the integrin family, and said “polypeptides with binding effect and affinity with the integrin family” refer to the sequences containing Arg-Gly-Asp or Arg-Gly-Asp-linker, and said linker (s) in the present invention refer to one or more different amino acids.
Dependencies are inferred from the claim text.